$FATE News
Last published 6d ago
- 6d agoFATEFATE THERAPEUTICS INC - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 6d agoFATEFate Therapeutics Reports Third Quarter 2026 Financial Results and Business UpdatesGlobeNewswireSafety profile presented at ASN Kidney Week 2026 across 29 autoimmune patients treated with a single dose of FT819 and fludarabine-free, less-intensive conditioning continues to be favorable, further supporting
- 1w agoFATEFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative and broadly accessible pipeline of induced
- 2w agoFATEFate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026GlobeNewswireActive LN patients in the Phase 1 study treated with FT819 and the less-intensive conditioning (bendamustine) regimen selected for the RECLAIM-LN study achieved 100% renal response at Month 6, with approximately 50%
- 1mo agoFATEFate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell TherapiesGlobeNewswireCommercial leader brings lupus nephritis and first-in-class launch experience as FT819 advances in the RECLAIM-LN Phase 2 trial Proven record in advancing breakthrough autoimmune therapies and establishing novel lupus
- 1mo agoFATEFate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026GlobeNewswireSAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell
- 2mo agoFATEFate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 MeetingGlobeNewswireSAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell
- 2mo agoFATEFate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare ConferenceGlobeNewswireSAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell
- 2mo agoFATEFate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus NephritisGlobeNewswireFirst patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819 toward a potential accelerated regulatory pathway
- 3mo agoFATEFate Therapeutics Reports Second Quarter 2026 Financial Results and Business UpdatesGlobeNewswireFirst lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated as an outpatient with same-day
- 3mo agoFATEFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell
- 4mo agoFATEFate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product CandidateGlobeNewswireFirst-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development Novel 13-point edited CAR T cell Built
- 4mo agoFATEFate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual MeetingGlobeNewswireSAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell
- 4mo agoFATEFate Therapeutics to Participate in Upcoming Third Quarter 2026 ConferencesGlobeNewswireSAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell
- 4mo agoGTBPNKTXFATECMPX+1A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting DrugsPR NewswireDrug discovery has long been a slow, expensive process of trial and error, and for a small clinical-stage company, every wasted experiment is capital ...
- 4mo agoFATEFate Therapeutics Appoints Laura Hamill to Board of DirectorsGlobeNewswireSAN DIEGO, June 15, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell
- 5mo agoCMPXCRBUFATEGTBP+1After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune CellGlobeNewswireIssued on behalf of GT Biopharma, Inc. Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for
- 5mo agoFATEGTBPIBRXIOVA+1Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE BetGlobeNewswireIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP) A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while
- 5mo agoFATEFate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual MeetingGlobeNewswireFT819 off-the-shelf CAR T-cell therapy product candidate continues to broaden patient access with 21 SLE patients now treated, including as outpatient administration in community hospitals Continued demonstration of
- 5mo agoFATEFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell
- 5mo agoFATEFate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual MeetingGlobeNewswireFT836 demonstrates meaningful reduction in target lesions without the use of conditioning chemotherapy in metastatic colorectal cancer Detection of FT836 in the peripheral blood and tumor tissue illustrates the unique
- 5mo agoGTBPIBRXFATENKTX+1The $13 Million Company Teaching the Immune System to Hunt CancerPR NewswireUSA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ: GTBP)...
- 5mo agoFATEFate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune DiseasesGlobeNewswireSAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell
- 5mo agoGERNBIOALCTXFATECell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative MarketsPR NewswireMarket News Updates News Commentary - Cell-based therapies are quickly becoming one of the most talked-about areas in healthcare as researchers move...
- 5mo agoGTBPFATENKTXIBRX+1Three TriKE Candidates In Clinic As NK Cell Engager Field ReorganizesPR NewswireThe case for natural killer cell-based immunotherapy has been one of the longer-running theses in clinical oncology. NK cells sit on the body's first ...
- 6mo agoGTBPARTVFATEIBRX+1Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth PhasePR NewswireMomentum around solid tumor cancer treatments is picking up fast as new technologies and therapies continue delivering encouraging results across...
- 6mo agoFATEFate Therapeutics Reports First Quarter 2026 Financial Results and Business UpdatesGlobeNewswireRECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initiate in the 2nd half
- 6mo agoFATEFate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual MeetingGlobeNewswireSingle dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity state (LLDAS) in active SLE Patients; durable B cell remodeling is exhibited by depletion of major B cell clones up to
- 6mo agoFATEFate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819GlobeNewswireFDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supports the acceleration of manufacturing readiness for therapies with expedited clinical development timelines Current
- 6mo agoFATEFate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune DiseasesGlobeNewswireSAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell
- 6mo agoFATEFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell
- 6mo agoFATEFate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 MeetingGlobeNewswireSAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell
- 6mo agoFATEFate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual MeetingGlobeNewswireSAN DIEGO, April 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell
- 7mo agoFATEFate Therapeutics to Participate in Upcoming Second Quarter 2026 ConferencesGlobeNewswireSAN DIEGO, April 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell
- 7mo agoFATEFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell
- 7mo agoIBRXFATEGUTSMBRXScalable Biotech Manufacturing Unlocks a $14B MarketPR NewswireUSANewsGroup.com News Commentary — The global cell therapy manufacturing market is hitting a pivotal inflection point. It's projected to surpass $7...
- 8mo agoFATEFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell
- 8mo agoFATEFate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare ConferenceGlobeNewswireSAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell
- 8mo agoFBLGFATEMESOLGVNCell Therapies Moving From Lab to Factory Floor, and the Stocks Behind ThemPR NewswireUSANewsGroup.com News Commentary — The global cell therapy market is projected to surpass $8.2 billion in 2026, driven by a wave of clinical...
- 8mo agoFATEFate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business UpdatesGlobeNewswireOutpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge Four systemic sclerosis patients and the first
- 8mo agoFATEIPSCTYO:4593IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightGlobeNewswireNew York, USA, Feb. 16, 2026 (GLOBE NEWSWIRE) -- IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight The iPSC-derived NK cells
- 9mo agoFATEFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell
- 9mo agoVRTXFATEMNKDARDXBreaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease MarketsPR NewswireThe medical world is shifting as the global market for next-gen treatments heads toward $88.85 billion by 2030[1], driven by a surge in funding for...
- 9mo agoARDXAVAIFATEMNKD+1Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease MarketsGlobeNewswireVANCOUVER, British Columbia, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary – The medical world is shifting as the global market for next-gen treatments heads toward $88.85 billion by 2030[1], driven
- 10mo agoFATEFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell
- 11mo agoFATEFate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell ProgramsGlobeNewswireFT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) patients now treated; first systemic sclerosis (SSc) patient treated First
- 11mo agoFATEFate Therapeutics to Present at Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswireSAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of
- 12mo agoFATEFate Therapeutics Reports Third Quarter 2025 Financial Results and Business UpdatesGlobeNewswireAuthorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate that Utilizes
- 1y agoFATEFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell
- 1y agoFATEFate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell TherapyGlobeNewswireAs of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive or no conditioning